To further confirm the crucial role of p53 in the ability of GnRH agonists to sensitize CRPC cells to chemotherapeutic drugs, we investigated the effects of a pretreatment with GnRH-A on the cytotoxic effects of docetaxel in p53-null PC3 prostate cancer cells. This evidence concerns the gene GNRH1 and Familial prostate cancer.